Concerns about anti-vascular endothelial growth factor therapy for exudative age-related macular degeneration treatment
10.3760/cma.j.issn.1005-1015.2010.01.02
- VernacularTitle:重视抗血管内皮生长因子疗法在渗出型老年性黄斑变性治疗应用中的问题
- Author:
Yusheng WANG
;
Huiyuan HOU
- Publication Type:Journal Article
- Keywords:
Macular Degeneration/drug therapy;
Choroidal neovascularization/drug therapy;
Antibodies,monoclonal/therapeutic use;
Antibodies,monoclonal/adverse effects;
Vascular endothelial growth factors
- From:
Chinese Journal of Ocular Fundus Diseases
2010;26(1):6-8
- CountryChina
- Language:Chinese
-
Abstract:
The introduction of anti-vascular endothelial growth factor (VEGF) therapy represents a landmark in the management of wet age-related macular degeneration (AMD).However,as a new therapy,several problems such as durability of the therapeutic effects,medication side effects,and medication selection have emerged.We should make appoint of improving the therapeutic effect and safety by realizing the limitation of the therapy,monitoring the clinical potential adverse reactions of anti-VEGF agents,and recommending individualized treatment.
